49 papers
HIV/AIDS research remains a critical frontier in global health, focusing on everything from understanding how the virus interacts with the human immune system to developing new treatments and vaccines. This field is constantly evolving, with scientists working tirelessly to improve patient outcomes and move closer to a functional cure. Because these discoveries happen rapidly, staying updated with the latest findings is essential for both experts and the public.
At Gist.Science, we bridge the gap between complex research and clear understanding by processing every new preprint in this category directly from medRxiv. We transform these dense scientific documents into both plain-language explanations and detailed technical summaries, ensuring that the latest insights into HIV and AIDS are accessible to everyone. Below are the most recent papers we have analyzed, offering a fresh look at the ongoing fight against the virus.
This study models the impact of abrupt USAID and CDC funding cuts in KwaZulu Natal, South Africa, revealing that such cessation would significantly increase HIV incidence and mortality by 2030, while restoring funds within 12 months and reallocating them to long-acting PrEP could substantially avert new infections and help realign the province with epidemic control goals.
This cross-sectional study conducted in Kampala, Uganda, reveals that approximately 3.2% of patients on antiretroviral therapy with undetectable viral loads yield false-negative results on rapid HIV diagnostic tests, a phenomenon significantly associated with higher CD4 counts and longer duration on treatment, suggesting that serial rapid testing alone may be insufficient for this population.
This mixed-methods study in India demonstrates that while a peer-led running intervention improves mental health for adolescents with perinatally acquired HIV, its effectiveness is significantly hindered for girls by gendered social barriers, highlighting the urgent need for gender-transformative program designs to ensure equitable outcomes.
This target trial emulation study utilizing routine data from Malawi's HIV program demonstrates that six-month antiretroviral therapy dispensing (6MMD) is associated with slightly but significantly higher retention rates at 12 and 24 months compared to shorter dispensing intervals.
This study analyzes 2016/17 and 2022/23 national survey data to reveal that while HIV testing uptake among young women in mainland Tanzania increased from 86% to 90%, it stagnated at 40% for adolescents, with consistent determinants including union status, higher education, and STI history, underscoring the need for age-specific intervention strategies.
This study utilizes an integrated pharmacokinetic-pharmacodynamic model to demonstrate that twice-yearly injectable lenacapavir achieves sustained protective concentrations against wild-type HIV and specific drug-resistant mutants, while also highlighting the risk of de novo resistance emergence upon discontinuation and the need for strategies to manage PrEP cessation.
This systematic review and meta-regression confirms that mathematical models used by UNAIDS accurately reflect the declining incidence levels and trends observed in population-representative studies across sub-Saharan Africa, though they fail to capture the epidemic's aging pattern and significantly underestimate incidence in non-representative groups such as pregnant women and key populations.
This modeling analysis of 24 US states projects that the median age of people living with diagnosed HIV will rise from 51 to 62 by 2040, with over half exceeding age 65, while highlighting significant state-level heterogeneities that necessitate tailored healthcare planning.
This study establishes a validated cut-off score of ≥30 on the 12-item Brief Berger HIV Stigma Scale as a sensitive screening tool for identifying psychosocial vulnerability among people living with HIV in Nigeria, revealing that concerns about public attitudes are a stronger predictor of vulnerability than internalized stigma.